Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-06-29 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
证券事务代表任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a securities affairs representative at Beijing Northland Biotechnology Co., Ltd. It details the appointment decision made at a board meeting, the qualifications of the appointee, and compliance with relevant laws. There is no financial data, no report or presentation content, and no mention of voting results or dividends. This fits the category of Board/Management Information (MANG), as it concerns a change in company personnel related to governance.
2025-06-29 Chinese
第六届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting's attendance, the approval of a loan application proposal, voting results, and procedural compliance. There is no financial report, earnings data, or detailed management discussion. The content focuses on board decisions and approvals, specifically regarding financing plans, but it is not a financing update itself. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification. Therefore, the classification is MANG with high confidence.
2025-06-15 Chinese
关于申请银行贷款的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the company's application for a bank loan, detailing the loan amount, purpose, board approval, and impact on the company. It does not contain financial statements, audit information, or detailed financial results. It is a financing update related to capital structure and funding activities. The document length is short (905 characters) and it is a direct announcement, not a report or presentation. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-06-15 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations of the company Beijing Northland Biotechnology Co., Ltd. It details the stock price movement over a recent period, the company's investigation into the causes, and a statement confirming no undisclosed material information affecting stock price. It also includes a risk warning to investors. There is no financial data, no report attached or referenced as being published, and no mention of annual or quarterly results, management changes, or other report types. The document is a regulatory announcement about stock trading activity and compliance with stock exchange rules. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-02 Chinese
投资者关系活动记录表
Investor Presentation Classification · 90% confidence The document is an investor relations activity record from Beijing Northland Biotech Co., Ltd., dated May 22, 2025. It details a specific investor relations event categorized as a 'specific object research' (特定对象调研), including questions and answers about the company's drug development, market potential, regulatory approval progress, commercialization plans, and production capacity. The document does not contain financial statements, earnings highlights, or regulatory certifications. It is not a report of financial results, audit, or management changes. It is also not a brief announcement or a report publication notice. The content is focused on investor relations communication and detailed Q&A, which aligns with the nature of an Investor Presentation (IP) rather than a formal earnings release or annual/interim report. Given the detailed discussion of company strategy, product pipeline, and market outlook, the best fit is Investor Presentation (IP). The document length is 3203 characters, which is consistent with a detailed presentation or communication rather than a full report.
2025-05-21 Chinese
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2024年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, agenda, voting procedures, and results of the 2024 Annual General Meeting (AGM) of Beijing Northland Biotech Co., Ltd. It details the legal compliance of the AGM process, including shareholder attendance, voting results on various proposals, and confirms the legality and validity of the meeting and its resolutions. The document does not contain financial statements or detailed financial performance data but focuses on the AGM procedures and voting outcomes. The document length is 4368 characters, which is relatively short but contains substantive content about the AGM itself, not just an announcement or a brief note. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2025-05-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.